Relationship of Soluble Lectin-Like Low-Density Lipoprotein Receptor-1 (sLOX-1) With Inflammation and Coronary Plaque Progression in Psoriasis

J Am Heart Assoc. 2023 Nov 21;12(22):e031227. doi: 10.1161/JAHA.123.031227. Epub 2023 Nov 20.

Abstract

Background: Psoriasis is a chronic inflammatory condition associated with coronary artery disease risk. Uptake of oxidized low-density lipoprotein by the lectin-like low-density lipoprotein receptor-1 triggers release of the soluble extracellular domain of the receptor (sLOX-1). We sought to characterize the relationship between sLOX-1, inflammation, and coronary plaque progression in psoriasis.

Methods and results: A total of 327 patients with psoriasis had serum sLOX-1 levels measured at baseline by an ELISA-based assay. Stratification by high-sensitivity C-reactive protein ≥4.0 mg/L (quartile 4), identified 81 participants who had coronary plaque phenotyping at baseline and were followed longitudinally by coronary computed tomography angiography. Subjects within high-sensitivity C-reactive protein quartile 4 were middle-aged (51.47±12.62 years), predominantly men (54.3%) with moderate psoriasis disease severity (6.60 [interquartile range, 3.30-13.40]). In the study cohort, participants with sLOX-1 above the median displayed increased vulnerable coronary plaque features. At baseline, sLOX-1 was associated with total burden (rho=0.296; P=0.01), noncalcified burden (rho=0.286; P=0.02), fibro-fatty burden (rho=0.346; P=0.004), and necrotic burden (rho=0.394; P=0.002). A strong relationship between sLOX-1, noncalcified burden (β=0.19; P=0.03), and fibro-fatty burden (β=0.29; P=0.003) was found in fully adjusted models at baseline and 1- and 4-year follow-up. Finally, coronary plaque features progressed over 1 year regardless of biologic or systemic treatment in subjects with high sLOX-1.

Conclusions: Patients with psoriasis with both high sLOX-1 and high-sensitivity C-reactive protein levels have increased coronary plaque burden associated with atherosclerotic plaque progression independent of biologic and systemic treatment. Thus, sLOX-1 might be considered as a promising marker in coronary artery disease risk estimation beyond traditional risk factors.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01778569.

Keywords: atherosclerosis; coronary plaque; inflammation; oxidized LDL; psoriasis; sLOX‐1.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Biomarkers* / blood
  • C-Reactive Protein / analysis
  • C-Reactive Protein / metabolism
  • Computed Tomography Angiography
  • Coronary Angiography
  • Coronary Artery Disease* / blood
  • Coronary Artery Disease* / diagnosis
  • Coronary Artery Disease* / diagnostic imaging
  • Disease Progression*
  • Female
  • Humans
  • Inflammation / blood
  • Male
  • Middle Aged
  • Plaque, Atherosclerotic* / blood
  • Psoriasis* / blood
  • Psoriasis* / complications
  • Psoriasis* / diagnosis
  • Risk Factors
  • Scavenger Receptors, Class E* / blood
  • Severity of Illness Index

Substances

  • Biomarkers
  • C-Reactive Protein
  • Scavenger Receptors, Class E
  • TNFRSF9 protein, human

Associated data

  • ClinicalTrials.gov/NCT01778569